- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04796272
Role of Individualized Versus Traditional Exercise in Combating Fatigue (REEN-SEP)
Role of Individualized Versus Traditional Exercise in Combating Fatigue in Fatigued Multiple Sclerosis Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic fatigue is a very common symptom reported (80%) by patients with multiple sclerosis (MS), regardless of the type of MS and level of disability. Despite the clinical importance of MS-related fatigue, pharmacological treatments remain quite ineffective in preventing or treating chronic fatigue.
Recently, physical activity has proven to be an effective therapy with benefits on chronic fatigue as well as on different functions (muscular, cardiorespiratory, cognitive, etc.). Nevertheless, the effects of physical exercise may vary between MS patients, as MS is a heterogeneous disease and does not affect each individual in the same way. The objective of this project will be to characterise the benefits of an exercise programme adapted to each individual's abilities compared to a traditional exercise programme with the aim of reducing perceived fatigue and improving the quality of life of Patients with multiple sclerosis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Saint-Étienne, France
- CHU de Saint-Etienne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18 to 70 years old
- Male or female
- With relapsing-remitting multiple sclerosis (RRMS) as defined by McDonald's 2010 criteria.
- Between 2 and 25 years from the onset of multiple sclerosis
- With a high level of fatigue, corresponding to a score of Fatigue Severity Scale> 4 and Fatigue questionnaire > 38.
- Expanded Disability Status Scale Score 5
- Testing ≥ 4 in all leg muscles.
- Ability to walk for 10 minutes without stopping (self-reported)
- Affiliates or beneficiaries of a social security scheme
- Having freely given their written consent after having been informed of the purpose, course of action and potential risks involved
Exclusion Criteria:
- Severe cerebellar spasticity or ataxia in either leg.
- Abnormal range of motion of the toes and/or ankle.
- Musculoskeletal injury that interferes with pedaling.
- High resting heart rate (>90 beats per minute).
- Blood pressure > 144/94 mmHg.
- Onset of a multiple sclerosis attack within 90 days prior to the study.
- Recent adjustment of any medication or drugs that may impact on fatigue, or taking stimulants for fatigue (e.g. Modafinil).
- Taking of neuro-active substances that may impair cortico-spinal excitability (hypnotics, antiepileptics, psychotropic drugs, muscle relaxants) throughout the study period.
- Contraindication to the application of a magnetic field
- History of co-morbid disease or conditions that would compromise the subject's safety during the study.
- Participation at the same time in another medical intervention study or having participated in such a study within 30 days prior to this study.
- Pregnant and Nursing Women
- Women of childbearing age without effective contraception
- Patient unable to understand the purpose and conditions of the study, incapable of giving consent
- Patient deprived of liberty or patient under guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Traditional exercise
fatigued multiple sclerosis patients with a traditional training program
|
Same training program for all patients in this group
|
|
Experimental: Individual exercise
tired multiple sclerosis patients with an adapted and individualized training program
|
Physical training program adapted and individualized according to each patient in this group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Chronic fatigue score
Time Frame: Month 3
|
assessed using the Fatigue Severity Scale (FSS) questionnaire before and after an individualized re-training program compared to a traditional re-training program in MS patients.
|
Month 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cardiorespiratory fitness
Time Frame: Month 3
|
evaluated by measuring the maximum oxygen consumption (VO2max) during an incremental exercise on a cycloergometer.
|
Month 3
|
|
Hematological parameters
Time Frame: Month 3
|
red blood cell and hemoglobin levels measured by spectrophotometry.
|
Month 3
|
|
Inflammatory parameters
Time Frame: Month 3
|
c-reactive protein
|
Month 3
|
|
quality of sleep
Time Frame: Month 3
|
actigraphy measurements and sleep diary records
|
Month 3
|
|
cortical activation level
Time Frame: Month 3
|
transcranial magnetic stimulation
|
Month 3
|
|
cortico-spinal excitability
Time Frame: Month 3
|
transcranial magnetic stimulation
|
Month 3
|
|
neuromuscular fatigue of peripheral function
Time Frame: Month 3
|
electrical nerve stimulation
|
Month 3
|
|
Analysis overall quality of life : Fatigue questionnaire
Time Frame: Month 3
|
Fatigue questionnaire by Modified Fatigue Impact Scale (MFIS) results
|
Month 3
|
|
Analysis overall quality of life :Quality of Life
Time Frame: Month 3
|
Quality of Life Questionnaire by SEP-59 results
|
Month 3
|
|
Analysis overall quality of life :Depression
Time Frame: Month 3
|
Depression Questionnaire by Center for Epidemiologic Studies Depression (CES-D) results
|
Month 3
|
|
Analysis overall quality of life : Sleep Quality
Time Frame: Month 3
|
Sleep Quality Questionnaire by Pittsburgh Sleep Quality Index (PSQ-I) results
|
Month 3
|
|
Analysis overall quality of life : Physical Activity
Time Frame: Month 3
|
Physical Activity Questionnaire by Godin Leisure-Time Exercise Questionnaire (GLTEQ) results
|
Month 3
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jean Philippe CAMDESSANCHE, MD PhD, CHU Saint-Etienne
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20CH032
- 2020-A00841-38 (Other Identifier: IDRCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on traditional training program
-
University GhentSpecial Research Fund, BelgiumCompletedChronical Rotator Cuff TendinopathyBelgium
-
National Cheng Kung UniversityCompletedAutism Spectrum Disorder
-
Chang Gung Memorial HospitalCompleted
-
Matej Bel UniversityMasaryk UniversityCompletedSoccer Performance | Plyometric Exercises | Speed | Microdosing | Explosive StrengthCzechia
-
National Cheng-Kung University HospitalNational Science and Technology CouncilRecruiting
-
National Cheng-Kung University HospitalNot yet recruitingDevelopmental Delay | Preterm Children
-
Shimaa Mohamed ReffatCairo UniversityCompleted
-
Pharos University in AlexandriaNot yet recruitingChronic Idiopathic Fatigue
-
Cairo UniversityCompleted
-
Cairo UniversityCompleted